Literature DB >> 23319058

Differential type I interferon-dependent transgene silencing of helper-dependent adenoviral vs. adeno-associated viral vectors in vivo.

Masataka Suzuki1, Terry K Bertin, Geoffrey L Rogers, Racel G Cela, Irene Zolotukhin, Donna J Palmer, Philip Ng, Roland W Herzog, Brendan Lee.   

Abstract

We previously dissected the components of the innate immune response to Helper-dependent adenoviral vectors (HDAds) using genetic models, and demonstrated that multiple pattern recognition receptor signaling pathways contribute to this host response to HDAds in vivo. Based on analysis of cytokine expression profiles, type I interferon (IFN) mRNA is induced in host mouse livers at 1 hour post-injection. This type I IFN signaling amplifies cytokine expression in liver independent of the nature of vector DNA sequences after 3 hours post-injection. This type I IFN signaling in response to HDAds administration contributes to transcriptional silencing of both HDAd prokaryotic and eukaryotic DNA in liver. This silencing occurs early and is mediated by epigenetic modification as shown by in vivo chromatin immunoprecipitation (ChIP) with anti-histone deacetylase (HDAC) and promyelocytic leukemia protein (PML). In contrast, self-complementary adeno-associated viral vectors (scAAVs) showed significantly lower induction of type I IFN mRNA in liver compared to HDAds at both early and late time points. These results show that the type I IFN signaling dependent transgene silencing differs between AAV and HDAd vectors after liver-directed gene transfer.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23319058      PMCID: PMC3616533          DOI: 10.1038/mt.2012.277

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  52 in total

1.  Innate immune response to adenoviral vectors is mediated by both Toll-like receptor-dependent and -independent pathways.

Authors:  Jiangao Zhu; Xiaopei Huang; Yiping Yang
Journal:  J Virol       Date:  2007-01-17       Impact factor: 5.103

2.  Type I IFN signaling on both B and CD4 T cells is required for protective antibody response to adenovirus.

Authors:  Jiangao Zhu; Xiaopei Huang; Yiping Yang
Journal:  J Immunol       Date:  2007-03-15       Impact factor: 5.422

3.  Histone modifications are associated with the persistence or silencing of vector-mediated transgene expression in vivo.

Authors:  Efren Riu; Zhi-Ying Chen; Hui Xu; Chen-Yi He; Mark A Kay
Journal:  Mol Ther       Date:  2007-04-24       Impact factor: 11.454

4.  Role for centromeric heterochromatin and PML nuclear bodies in the cellular response to foreign DNA.

Authors:  Cleo L Bishop; Michal Ramalho; Nachiket Nadkarni; Wing May Kong; Christopher F Higgins; Nina Krauzewicz
Journal:  Mol Cell Biol       Date:  2006-04       Impact factor: 4.272

5.  Pseudo-hydrodynamic delivery of helper-dependent adenoviral vectors into non-human primates for liver-directed gene therapy.

Authors:  Nicola Brunetti-Pierri; Gary E Stapleton; Donna J Palmer; Yu Zuo; Viraj P Mane; Milton J Finegold; Arthur L Beaudet; Michelle M Leland; Charles E Mullins; Philip Ng
Journal:  Mol Ther       Date:  2007-02-06       Impact factor: 11.454

6.  Toll-like receptor 9 triggers an innate immune response to helper-dependent adenoviral vectors.

Authors:  Vincenzo Cerullo; Michael P Seiler; Viraj Mane; Nicola Brunetti-Pierri; Christian Clarke; Terry K Bertin; John R Rodgers; Brendan Lee
Journal:  Mol Ther       Date:  2007-02       Impact factor: 11.454

7.  Improved hepatic transduction, reduced systemic vector dissemination, and long-term transgene expression by delivering helper-dependent adenoviral vectors into the surgically isolated liver of nonhuman primates.

Authors:  Nicola Brunetti-Pierri; Thomas Ng; David A Iannitti; Donna J Palmer; Arthur L Beaudet; Milton J Finegold; K Dee Carey; William G Cioffi; Philip Ng
Journal:  Hum Gene Ther       Date:  2006-04       Impact factor: 5.695

8.  In vivo administration of lentiviral vectors triggers a type I interferon response that restricts hepatocyte gene transfer and promotes vector clearance.

Authors:  Brian D Brown; Giovanni Sitia; Andrea Annoni; Ehud Hauben; Lucia Sergi Sergi; Anna Zingale; Maria Grazia Roncarolo; Luca G Guidotti; Luigi Naldini
Journal:  Blood       Date:  2007-04-01       Impact factor: 22.113

9.  Modulation of TNFalpha, a determinant of acute toxicity associated with systemic delivery of first-generation and helper-dependent adenoviral vectors.

Authors:  V P Mane; G Toietta; W M McCormack; I Conde; C Clarke; D Palmer; M J Finegold; L Pastore; P Ng; J Lopez; B Lee
Journal:  Gene Ther       Date:  2006-05-18       Impact factor: 5.250

Review 10.  PML and PML nuclear bodies: implications in antiviral defence.

Authors:  Roger D Everett; Mounira K Chelbi-Alix
Journal:  Biochimie       Date:  2007-01-27       Impact factor: 4.079

View more
  30 in total

1.  Five Years of Successful Inducible Transgene Expression Following Locoregional Adeno-Associated Virus Delivery in Nonhuman Primates with No Detectable Immunity.

Authors:  Mickaël Guilbaud; Marie Devaux; Celia Couzinié; Johanne Le Duff; Alice Toromanoff; Céline Vandamme; Nicolas Jaulin; Gwladys Gernoux; Thibaut Larcher; Philippe Moullier; Caroline Le Guiner; Oumeya Adjali
Journal:  Hum Gene Ther       Date:  2019-04-16       Impact factor: 5.695

2.  One microRNA controls both angiogenesis and TLR-mediated innate immunity to nucleic acids.

Authors:  Geoffrey L Rogers; Roland W Herzog
Journal:  Mol Ther       Date:  2014-02       Impact factor: 11.454

Review 3.  In Vivo Hematopoietic Stem Cell Transduction.

Authors:  Maximilian Richter; Daniel Stone; Carol Miao; Olivier Humbert; Hans-Peter Kiem; Thalia Papayannopoulou; André Lieber
Journal:  Hematol Oncol Clin North Am       Date:  2017-10       Impact factor: 3.722

4.  Somatic Editing of Ldlr With Adeno-Associated Viral-CRISPR Is an Efficient Tool for Atherosclerosis Research.

Authors:  Kelsey E Jarrett; Ciaran Lee; Marco De Giorgi; Ayrea Hurley; Baiba K Gillard; Alexandria M Doerfler; Ang Li; Henry J Pownall; Gang Bao; William R Lagor
Journal:  Arterioscler Thromb Vasc Biol       Date:  2018-09       Impact factor: 8.311

Review 5.  Adeno-associated virus as a gene therapy vector: strategies to neutralize the neutralizing antibodies.

Authors:  Majid Lotfinia; Meghdad Abdollahpour-Alitappeh; Behzad Hatami; Mohammad Reza Zali; Morteza Karimipoor
Journal:  Clin Exp Med       Date:  2019-05-03       Impact factor: 3.984

Review 6.  Immune responses to AAV vectors: overcoming barriers to successful gene therapy.

Authors:  Federico Mingozzi; Katherine A High
Journal:  Blood       Date:  2013-04-17       Impact factor: 22.113

7.  Oncolytic Adenovirus Armed with BiTE, Cytokine, and Checkpoint Inhibitor Enables CAR T Cells to Control the Growth of Heterogeneous Tumors.

Authors:  Caroline E Porter; Amanda Rosewell Shaw; Youngrock Jung; Tiffany Yip; Patricia D Castro; Vlad C Sandulache; Andrew Sikora; Stephen Gottschalk; Michael M Ittman; Malcolm K Brenner; Masataka Suzuki
Journal:  Mol Ther       Date:  2020-02-24       Impact factor: 11.454

8.  Copackaged AAV9 Vectors Promote Simultaneous Immune Tolerance and Phenotypic Correction of Pompe Disease.

Authors:  Phillip A Doerfler; Adrian G Todd; Nathalie Clément; Darin J Falk; Sushrusha Nayak; Roland W Herzog; Barry J Byrne
Journal:  Hum Gene Ther       Date:  2016-01       Impact factor: 5.695

Review 9.  Recent advances in oncolytic adenovirus therapies for cancer.

Authors:  Amanda Rosewell Shaw; Masataka Suzuki
Journal:  Curr Opin Virol       Date:  2016-07-02       Impact factor: 7.090

Review 10.  Current and Future Treatments for Lysosomal Storage Disorders.

Authors:  David P W Rastall; Andrea Amalfitano
Journal:  Curr Treat Options Neurol       Date:  2017-11-04       Impact factor: 3.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.